Articles

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study

Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht
Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL
Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Department of Central Diagnostic Laboratory - Research, University Medical Center Utrecht, Utrecht University, Utrecht
Department of Central Diagnostic Laboratory - Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Department of Hematology, Erasmus University Medical Center, Rotterdam
Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht
Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht
Department of Hematology, Erasmus University Medical Center, Rotterdam
Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital University Medical Center Rotterdam, Rotterdam
Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam
Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam
Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht
Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, Chicago, IL
Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht
Haematologica Early view Feb 26, 2026 https://doi.org/10.3324/haematol.2025.289105